APA (7th ed.) Citation

Rosell, R., Jantus-Lewintre, E., Cao, P., Cai, X., Xing, B., Ito, M., . . . Arrieta, O. (2024). KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination. Cell Communication & Signaling, 22(1), 1. https://doi.org/10.1186/s12964-024-01667-x

Chicago Style (17th ed.) Citation

Rosell, Rafael, et al. "KRAS-mutant Non-small Cell Lung Cancer (NSCLC) Therapy Based on Tepotinib and Omeprazole Combination." Cell Communication & Signaling 22, no. 1 (2024): 1. https://doi.org/10.1186/s12964-024-01667-x.

MLA (9th ed.) Citation

Rosell, Rafael, et al. "KRAS-mutant Non-small Cell Lung Cancer (NSCLC) Therapy Based on Tepotinib and Omeprazole Combination." Cell Communication & Signaling, vol. 22, no. 1, 2024, p. 1, https://doi.org/10.1186/s12964-024-01667-x.